Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer

Abstract

In the present study, we assessed the relationship of serum insulin levels and three surrogate markers of recurrence, T stage, PSA, and Gleason score, in men with localized prostate cancer. Participants in our study were found through urology and radiation oncology clinics, and all eligible patients were asked to take part. All patients were asymptomatic and had been initially diagnosed on the basis of rising PSA or abnormal physical examination. Histological confirmation of diagnosis was obtained for all subjects. Serum insulin levels were determined by chemoluminescent assay with a standard, commercially available instrument. Patients were divided into three previously defined risk groups: Low risk : PSA ⩽10, stage ⩽T2a, or Gleason grade ⩽6. Medium risk : 10 <PSA ⩽15, Gleason 7 or stage T2b. High risk : Gleason >7, tumour in seminal vesicle biopsy, PSA >15 or stage T2c or T3. One hundred and sixty-three men with prostate cancer were studied. There was a significant increase in serum insulin with risk group ( P =0.003, one way anova). Tukey's multiple range test showed that the insulin levels of high risk patients were significantly higher than the insulin levels of medium and low risk patients ( P =0.05) but the insulin levels of medium and low risk patients were not significantly different from one another. Multivariate linear regression, with insulin as the dependent variable, Gleason score, PSA, and T stage (T1, T2, T3) as the independent variables, was significant overall ( P <0.001, r 2 =0.120). Increased T stage was independently correlated with increased serum insulin levels ( P <0.001). Gleason score was negatively, insignificantly correlated with serum insulin level ( P =0.059). The positive correlation of PSA and insulin level was not significant ( P =0.097). To assure normal distribution of insulin and PSA values, the regression was repeated with log (insulin) as the dependent variable, log (PSA), T stage (T1, T2, T3), and Gleason score as independent variables. The regression was significant overall ( P =0.002, r 2 =0.095). Increased T stage was independently correlated with increased log (insulin level) ( P =0.026). Gleason score was negatively, insignificantly correlated with log (insulin) level ( P =0.728). The positive correlation of log (PSA) and log (insulin) levels was significant ( P =0.010). The relationship between increased insulin level and advanced tumour stage in prostate cancer we describe here is biologically quite plausible, since insulin is a growth factor. Further studies may document whether serum insulin levels might be a useful biomarker of prostate cancer stage. British Journal of Cancer ...

Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer

“…Significant positive correlations were found only between fasting insulin indices and cancer spread in the patients with highly and moderately differentiated endometrial adenocarcinomas which, as mentioned earlier, are mainly type I (Table 3). The association noted is most probably not an accidental coincidence due to the following reasons: 1) quite solid statistical significance was reached regarding the correlation analysis results; 2) the association of hyperinsulinemia with cancer progression is biologically explainable (there are several mechanisms capable of mediating the insulin growth-promoting effect in endometrium); 3) similar results were obtained when studying hyperinsulinemia's impact on the course of breast and prostate cancer (Goodwin et al 2002;Lehrer et al 2002). As a whole, this allows us to consider the data obtained to be regular and reproducible.…”

Nutrigenetics and Prostate Cancer: 2011 and Beyond

“…The low plasma glucose levels will lead to lower insulin secretion as compared with high glucose levels, which may be protective to prostate cancer, as insulin per se is mitogenic and it has a growth-stimulatory effect on prostate cancer [141]. This hypothesis would be supported by other studies showing a positive association between high serum insulin levels and increased prostate cancer risk [141,142,143]. It does not, however, explain the fact that an increased risk of prostate cancer in JAZF1 variants has also been suggested [138].…”

Insulin Resistance and Coronary Heart Disease in Nondiabetic Individuals

“…Reports have also been published suggesting a relationship between insulin resistance/hyperinsulinemia and both colorectal and prostate cancer. As with breast cancer, the evidence consists of reports that both cancers are more likely to occur in individuals who are overweight 11 and/or have type 2DM, as well as the presence of higher plasma insulin concentrations in patients with colorectal or prostate cancer [60][61][62][63][64][65][66][67][68].…”